Jump to content

Critical Path Institute

Add links
From Wikipedia, the free encyclopedia

This is an old revision of this page, as edited by Bender the Bot (talk | contribs) at 02:06, 16 December 2019 (HTTP → HTTPS for Food and Drug Administration, replaced: http://www.fda.gov/ → https://www.fda.gov/ (3)). The present address (URL) is a permanent link to this revision, which may differ significantly from the current revision.

Critical Path Institute
Founded2005
Legal status501(c)(3) nonprofit organization
ServicesImprovement of the drug development process.
President and CEO
Joseph Scheeren
Websitec-path.org

Critical Path Institute (C-Path) is a nonprofit organization created to improve the drug development process; its consortia include more than 1,600 scientists from government regulatory and research agencies, academia, patient organizations, and bio-pharmaceutical companies.[1][2][3][4]

Background

The U.S. Food and Drug Administration (FDA) launched the Critical Path Initiative in 2004 to transform the way FDA-regulated medical products are developed, evaluated, and manufactured.[5] C-Path was created as an independent organization to respond to the needs outlined in the FDA’s initiative and with support and funding from the FDA, Science Foundation Arizona, and the Tucson, Arizona community. It operates as a neutral third party to enable scientists from the regulated industry and international regulatory agencies to work together with scientists from academia and patient groups to improve the drug development process.[4][6]

Approach

In the interest of national and global public health, C-Path develops large databases of aggregated clinical trial data that can be used to study disease progression. These data are also used to develop and qualify biomarkers and clinical outcome assessment instruments that are shared with the greater community for use in drug development. C-Path also develops quantitative models to facilitate the design of efficient clinical trials.[4][7][8][9]

C-Path Programs

C-Path programs are focused on reducing the time, cost, and risk of drug development and regulatory review. Where appropriate, C-Path forms consortia that are public/private partnerships[10] that aim to improve the drug development process.[11][12][13][14]

  • The Predictive Safety Testing Consortium (PSTC) works to find improved safety biomarkers to detect drug induced toxicity.[15][16]
  • The Patient-Reported Outcome (PRO) Consortium develops, evaluates, and qualifies PRO instruments (e.g., questionnaires) for use in clinical trials designed to assess the safety and effectiveness of medical products. [14]
  • The Critical Path to TB Drug Regimens (CPTR) aims to accelerate the development of new, safe, and highly effective tuberculosis treatment regimens with shortened durations of therapy.[17]
  • The Polycystic Kidney Disease (PKD) Consortium evaluates the evidence supporting total kidney volume (TKV) as a biomarker for assessing the progression of autosomal dominant PKD.[18]
  • The Critical Path for Alzheimer's Disease (CPAD) aims to increase the efficiency of the development process of new treatments for Alzheimer disease (AD) and related neurodegenerative disorders with impaired cognition and function. [19]
  • The Critical Path for Parkinson's (CPP) works to improve the clinical trial process.[19]
  • The Data Collaboration Center (DCC) develops data solutions for scientific research.
  • The Duchenne Regulatory Science Consortium (D-RSC) supports collaborative research through shared data access and drug development tools.
  • The Electronic Patient-Reported Outcome Consortium (e-PRO) supports the collection of patient-focused outcomes data in clinical trials.
  • The Huntington’s Disease Regulatory Science Consortium (HD-RSC) aims to accelerate the regulatory approval of Huntington’s disease therapies.
  • The International Neonatal Consortium (INC) seeks to forge a predictable regulatory path for evaluating the safety and effectiveness of therapies for neonates.
  • The Multiple Sclerosis Outcome Assessments Consortium (MSOAC) works to qualify a new measure of disability as a primary or secondary endpoint for future trials of MS therapies.
  • The Type 1 Diabetes Consortium (T1D) works to qualify islet autoimmunity antibodies as prognostic biomarkers.
  • The goal of the Transplant Therapeutics Consortium (TTC) is to accelerate the medical product development process for transplantation.
  • The TB-Platform for Aggregation of Clinical TB Studies (TB-PACTS) curates and standardizes Phase III tuberculosis (TB) clinical trial data.
  • The successfully completed Pediatric Trials Consortium worked toward the efficient evaluation of innovative drugs, biologics, and devices for children.

Location

C-Path is headquartered in Tucson, Arizona. Raymond L. Woosley, M.D., Ph.D. founded C-Path in 2005 and is President Emeritus. Joseph Scheeren, PharmD, is currently C-Path's President and Chief Executive Officer. The Board of Directors includes former Pfizer CFO Alan Levin and biochemist Paula J. Olsiewski.[20]

References

  1. ^ Woosley, R. L. "The FDA’s Critical Path Initiative." Archived 2010-10-26 at the Wayback Machine PharmacoVigilance Review 1.3 (August 2007): 16-18
  2. ^ U.S. Food and Drug Administration. The Critical Path Initiative: Transforming the Way FDA-Regulated Products are Developed, Evaluated, Manufactured, and Used April 2009
  3. ^ FDA: Paving the Pathway for Innovation Archived 2011-06-11 at the Wayback Machine
  4. ^ a b c Woodcock, J; Woosley, R (2008). "The FDA critical path initiative and its influence on new drug development". Annual Review of Medicine. 59: 1–12. doi:10.1146/annurev.med.59.090506.155819. PMID 18186700.
  5. ^ "18 Ideas to Reform Health Care Now." Reader's Digest, November 2008.
  6. ^ Coons, Stephen Joel (2009). "The FDA's critical path initiative: A brief introduction". Clinical Therapeutics. 31 (11): 2572–3. doi:10.1016/j.clinthera.2009.11.035. PMID 20110002.
  7. ^ Woosley, R. L.; Cossman, J. (2007). "Drug Development and the FDA's Critical Path Initiative" (PDF). Clinical Pharmacology & Therapeutics. 81 (1): 129–33. doi:10.1038/sj.clpt.6100014.
  8. ^ Mattes, William B. (2008). "Public Consortium Efforts in Toxicogenomics". In Mendrick, Donna L.; Mattes, William B. (eds.). Essential Concepts in Toxicogenomics. Methods in Molecular Biology. Vol. 460. pp. 221–238. doi:10.1007/978-1-60327-048-9_11. ISBN 978-1-58829-638-2. PMID 18449490.
  9. ^ Goodsaid, FM; Frueh, FW; Mattes, W (2008). "Strategic paths for biomarker qualification". Toxicology. 245 (3): 219–23. doi:10.1016/j.tox.2007.12.023. PMID 18280028.
  10. ^ "Critical Path Initiative". Fda.gov. Retrieved 2011-03-27. Cite web requires |website= (help) [verification needed]
  11. ^ Woosley, RL; Myers, RT; Goodsaid, F (2010). "The Critical Path Institute's Approach to Precompetitive Sharing and Advancing Regulatory Science". Clinical Pharmacology & Therapeutics. 87 (5): 530–3. doi:10.1038/clpt.2010.27.
  12. ^ "FDA Announces Partnership with Critical Path Institute to Conduct Essential Research to Spur Medical Innovation"
  13. ^ Ismail, Kola; Landis, John (2004). "Opinion: Can the pharmaceutical industry reduce attrition rates?". Nature Reviews Drug Discovery. 3 (8): 711–6. doi:10.1038/nrd1470.
  14. ^ a b U.S. Department of Health and Human Services Food and Drug Administration. "Innovation or Stagnation: Challenges and Opportunity on the Critical Path to New Medical Products." March 2004.
  15. ^ Goodsaid, F. M., F. W. Frueh, and W. B. Mattes. "The Predictive Safety Testing Consortium: A Synthesis of the Goals, Challenges and Accomplishments of the Critical Path." Drug Discovery Today: Technologies 4.2(2007): 47-50
  16. ^ Mattes, WB; Walker, EG (2009). "Translational toxicology and the work of the predictive safety testing consortium". Clinical Pharmacology and Therapeutics. 85 (3): 327–30. doi:10.1038/clpt.2008.270. PMID 19158666.
  17. ^ "The Critical Path to TB Regimens Initiative". Tballiance.org. Archived from the original on 2011-04-27. Retrieved 2011-03-27.
  18. ^ "Mayo Clinic Translational Polycystic Kidney Disease (PKD) Center;" "Building a Drug Development Machine." Archived 2011-01-16 at the Wayback Machine
  19. ^ a b Romero, K; De Mars, M; Frank, D; Anthony, M; Neville, J; Kirby, L; Smith, K; Woosley, RL (2009). "The Coalition Against Major Diseases: developing tools for an integrated drug development process for Alzheimer's and Parkinson's diseases". Clinical Pharmacology and Therapeutics. 86 (4): 365–7. doi:10.1038/clpt.2009.165. PMID 19763117.
  20. ^ "People | Critical Path Institute". c-path.org. Retrieved 2019-08-10.
Retrieved from "https://en.wikipedia.org/w/index.php?title=Critical_Path_Institute&oldid=930955971"